P21-Activated Kinase 2-Mediated β-Catenin Signaling Promotes Cancer Stemness and Osimertinib Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer

Investigators observed that the suppression of p21-activated kinase 2 (PAK2) via knockdown or pharmacological targeting with PAK inhibitors markedly restored the response of osimertinib-resistant NSCLC cells to osimertinib both in vitro and in vivo.